Previous Close | 127.88 |
Open | 129.51 |
Bid | 129.50 x 1100 |
Ask | 0.00 x 800 |
Day's Range | 128.92 - 130.98 |
52 Week Range | 79.29 - 133.56 |
Volume | |
Avg. Volume | 3,792,085 |
Market Cap | 158.622B |
Beta (5Y Monthly) | 1.50 |
PE Ratio (TTM) | 70.75 |
EPS (TTM) | 1.85 |
Earnings Date | Apr 18, 2024 - Apr 22, 2024 |
Forward Dividend & Yield | 3.35 (2.56%) |
Ex-Dividend Date | Feb 02, 2024 |
1y Target Est | 129.82 |
Subscribe to Yahoo Finance Plus to view Fair Value for BX
(Bloomberg) -- Blackstone Chief Executive Officer Steve Schwarzman said the private credit industry will expand further even as critics warn of a bubble developing in the asset class. Most Read from BloombergLondon Insurers Face Baltimore Bridge Payouts Worth BillionsBiden Gains Ground Against Trump in Six Key States, Poll ShowsJapan Amps Up Intervention Threat as Yen Hits Lowest Since 1990Dubai Is Losing Its Allure for Wealthy RussiansChina Property Crisis Is Rippling Through Its Biggest BanksT
The vaccine maker announced that Blackstone Life Sciences has agreed to fund up to $750 million for its flu program.
Moderna on Wednesday said Blackstone's life sciences arm would offer $750 million to help fund development of its flu vaccines, bolstering the company's efforts to advance multiple vaccines in the face of a steep decline in sales of its COVID-19 shots. Moderna is developing several new vaccines, including for cancer and respiratory syncytial virus (RSV), resulting in high research and development spending. The funding will reduce R&D expenses, although Moderna said it still plans to spend about $4.5 billion this year.